U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Merete Medical GmbH - 571091 - 07/05/2022
  1. Warning Letters

CLOSEOUT LETTER

Merete Medical GmbH MARCS-CMS 571091 —

Product:
Medical Devices
Recipient:
Recipient Name
Alexia Anapliotis
Recipient Title
CEO
Merete Medical GmbH

Alt-Lankwitz 102
12247 Berlin
Germany

Issuing Office:
Center for Devices and Radiological Health

United States

Dear Alexia Anapliotis:

The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter (CMS 571091, dated December 31, 2018). Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
CAPT Raquel Peat, PhD, MPH, USPHS 
Director 
OHT6: Office of Orthopedic Devices
Office of Product Evaluation and Quality 
Center for Devices and Radiological Health


CC US Agent:
Marc Kneissler
One Lincoln Centre
18W140 Butterfield Road, 15th Floor
Oakbrook Terrace, IL US 60181
Email: Mkneissler@Merete-Medical.Com

Back to Top